Company Profile

Artificial Cell Technologies Inc (AKA: ACT)
Profile last edited on: 3/28/17      CAGE: 46K66      UEI: FA75DFVZ55D1

Business Identifier: Vaccines for RSV and Malaria
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5 Science Park Suite 13
New Haven, CT 06511
   (203) 772-3430
Location: Single
Congr. District: 03
County: New Haven

Public Profile

Artificial Cell Technologies, Inc. (ACT) is a development-stage biotechnology company developing unique synthetic vaccines utilizing a proprietary and patent-protected technology platform of ultra-thin multilayer polypeptide nanofilms. The company’s headquarters and laboratory facilities are located in New Haven, CT. ACT engineers and produces multilayer nanofilm-based vaccines using a method known as electrostatic layer-by-layer self-assembly. Polypeptides with alternating opposite net electrical charge are assembled one layer at a time and adhere to the surface by electrostatic attraction. Key immunogenic epitopes from pathogenic organisms are incorporated into the nanofilm structure or on its surface during assembly. We call the resulting synthetic antigen carriers “Artificial Viruses”. ACT’s technology represents an entirely new approach to vaccines that is uniquely capable of more fully mimicking the immunogenic properties of a pathogenic organism and at the same time influencing the molecular and biological pathways of immune response. 

 Advantages of ACT’s vaccine technology include: Increases the immunogenicity of weakly or non-immunogenic antigens without the use of adjuvants Reduces antigen dose required for immunization dramatically reducing cost of materials Rapid synthetic manufacture with no egg or cell culture required, greatly reducing the chance of contamination and allowing a much faster time to market Flexible design and production platform readily allows for multivalent or combination vaccines Constructs are shelf stable at room temperature with a long shelf life; no cold chain storage required ACT's lead product candidates are vaccines for Respiratory Syncytial Virus (RSV) and malaria. Our development programs in both RSV and malaria include collaborations with top academic as well as government partners. ACT is now preparing its first IND filing to begin human clinical trials of an RSV vaccine candidate which utilizes ACT's proprietary ultra-thin multilayer polypepti

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 2 NIH $3,302,977
Project Title: Synthetic Nanocapsule Malaria Vaccines
2014 1 NIH $110,923
Project Title: Formulation of Lbl Microparticle Vaccine in Microneedle Array for Intradermal Del
2012 2 NIH $593,492
Project Title: Synthetic Nanoparticle Vaccines for RSV

Key People / Management

  Donald S Masters -- President and CEO

  Jim Boyd -- VP of Chemistry

  Donald T Haynie

  Thomas P Malone -- CFO and VP of Regulatory Affairs

  Jeff Powell -- VP of Immunology

  Thomas J Powell

  Joanna Price

Company News

There are no news available.